Company Overview and News

0
Doors Open Again: Big Luxury Hotel Boom for Greece

2018-06-12 thenationalherald
ATHENS – With many hotels shuttered during a more than eight-year-long economic and austerity, a run of record tourism seasons is leading to more luxury hotel investments despite fierce competition from services such as Airbnb which give people whole apartments or homes for around the same price.
500413 THOMASCOOK

0
Thomas Cook (India) Limited - Press Release

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

0
GoAir ropes in ex-EasyJet exec Vrieswijk as new CEO

2018-06-06 freepressjournal.in
Mumbai : Budget carrier GoAir has appointed former EasyJet executive Cornelis (Cor) Vrieswijk as its new chief executive officer, four months after Wolfgang Prock-Schauer quit the same position to join the rival IndiGo.
500413 THOMASCOOK

0
Ex-EasyJet executive Cornelis Vrieswijk is GoAir#39;s new CEO

2018-06-05 moneycontrol
Budget carrier GoAir has appointed former EasyJet executive Cornelis (Cor) Vrieswijk as its new chief executive officer, four months after Wolfgang Prock-Schauer quit the same position to join the rival IndiGo.
500413 THOMASCOOK

0
Quess eyes majority stake in Simpliance

2018-06-04 thehindubusinessline
The board of Quess Corp, Thomas Cook’s Indian arm, on Monday approved the acquisition of an additional 8 per cent equity in Simpliance Technologies Pvt Ltd. Following the acquisition, Quess’s stake in Simpliance will increase to 53 per cent and will become its subsidiary. Simpliance provides technology-based governance, and risk and compliance solutions to organisations varying from large corporates to start-ups.
PNJZY 500413 532461 PNB THOMASCOOK

41
Market Live: Sensex up 150 pts, Midcap underperforms; Tech Mahindra, ONGC jump

2018-05-31 moneycontrol
Indian Oil Corporation, which has for decades been India's biggest company by turnover, last week posted a record net profit of Rs 21,346 crore in the fiscal year ended March 31, 2018 (FY 2017-18), up 12 per cent from Rs 19,106 crore in the last fiscal.
IOC 500325 JIPKY BHUSANSTL TCHQY 532755 532754 535754 UCLQY 500570 CLNDY 500055 RLNIY 500413 AXB EVSJF 532627 530965 ULTRACEMCO TECHM 500182 AXBA 500180 520051 TCS COALINDIA RELIANCE PUNJLLOYD GMQRY GMRINFRA 532538 TTNQY 533278 532215 THOMASCOOK 532540 AXISBANK RIGD HDFCBANK HEROMOTOCO TATAMOTORS ORIENTCEM ESI IBN UCLQF JPASSOCIAT 539207 AXBKY 532532 ICICIBANK 532693 HDB 532174 JAMNAAUTO JPPOWER HRTQY MANPASAND TTM

0
Thomas Cook (India) Limited - AGM/Book Closure

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

0
Thomas Cook (India) Limited - Press Release

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

7
BHEL, BEL, Coal India, BPCL, IOB results eyed

2018-05-28 thehindubusinessline
Apollo Microsystems, Asahi Songwon Colours, Ashoka Buildcon, Balmer Lawrie, Bedmutha, BEL, BHEL, BPCL, Coal India, Cochin Minerals, Datamatics, Deccan Cement, Dish TV, D-Link India, Force Motors, Galaxy Surfactants, Glenmark Pharma, IOB, Ipca Laboratories, Jyothi, M&M, Max India, MMTC, Parsvanath, Sundram Brake, Thomas Cook, TTK Health, Unichem Labs, Uttam Sugar and Zenith Exports are some of the companies that will declare their Q4/FY results on Tuesday.
IPCALAB 500413 523319 533271 FORCEMOT BALMLAWRIE ASHOKA ZENITHEXPO 533278 THOMASCOOK 512553 500271 524494 MAX CLNDY COALINDIA 500033 MXGQY

48
Sun, sea, sand … and Warren Buffett? China’s tropical Hainan wants the big names to come and invest

2018-05-23 scmp
After Beijing says it will turn the island into a huge free-trade zone, the local government publishes a list of the world’s biggest business names it wants to talk to about setting up shop there
BRK.A MS.PRI 500413 MS.PRK TWX MS.PRE MS.PRF MS.PRG MS MS.PRA TWC THOMASCOOK

0
Thomas Cook (India) Limited - Trading Window

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...